Breaking News
Mrudula Kulkarni

Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
FDA grants Zydus priority review for saroglitazar NDA in PBC, setting a November 27, 2026 PDUFA date on Phase 3 EPICS-III data.
Mrudula Kulkarni

Samsung Bioepis launches OPUVIZ, its aflibercept biosimilar referencing Eylea, as its fifth directly commercialized biosimilar across European markets.
Pharma Now Editorial Team

Sanofi's AccelRare receives Class A medical device classification in India, setting a regulatory reference point for AI pre-diagnostic tools in emerging markets.
Pharma Now Editorial Team

AstraZeneca secured 11 CDSCO approvals in FY26 as India revenue rose 33% YoY to Rs. 22.76 billion, with oncology contributing Rs. 16.1 billion.
Pharma Now Editorial Team
